» Articles » PMID: 10798601

Gene-marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease

Overview
Journal J Clin Immunol
Publisher Springer
Date 2000 May 8
PMID 10798601
Authors
Affiliations
Soon will be listed here.
Abstract

In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.

References
1.
Hanenberg H, Xiao X, Dilloo D, Hashino K, Kato I, Williams D . Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996; 2(8):876-82. DOI: 10.1038/nm0896-876. View

2.
LEVY J, Muldoon R, Zolotukhin S, Link Jr C . Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells. Nat Biotechnol. 1996; 14(5):610-4. DOI: 10.1038/nbt0596-610. View

3.
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V . Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1998; 20(8):631-8. DOI: 10.1038/sj.bmt.1700944. View

4.
Miller A . Retroviral vectors. Curr Top Microbiol Immunol. 1992; 158:1-24. DOI: 10.1007/978-3-642-75608-5_1. View

5.
Vassilopoulos D, Kovacs B, Tsokos G . TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol. 1995; 155(4):2269-81. View